Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)

Naoto Yokogawa, Akiko Tanikawa, Masayuki Amagai, Yukihiko Kato, Yoko Momose, Satoru Arai, Hikaru Eto, Takaharu Ikeda, Fukumi Furukawa

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupusrelated skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Methods: Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity. Results: Twenty-seven patients, including 17 with SLE (6 with SLE/Sjögren's syndrome), were analyzed retrospectively. Twenty-three patients (85 %) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p<0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 %, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p<0.0001). Conclusions: CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.

Original languageEnglish
Pages (from-to)318-322
Number of pages5
JournalModern Rheumatology
Volume23
Issue number2
DOIs
Publication statusPublished - 2013 Mar

Fingerprint

Cutaneous Lupus Erythematosus
Hydroxychloroquine
Skin Diseases
Systemic Lupus Erythematosus
Skin Manifestations
Prednisolone
Japan
Multivariate Analysis
Smoking
Clinical Trials

Keywords

  • Cutaneous lupus erythematosus
  • Cutaneous lupus erythematosus disease area and severity index (CLASI)
  • Hydroxychloroquine
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology
  • Medicine(all)

Cite this

Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). / Yokogawa, Naoto; Tanikawa, Akiko; Amagai, Masayuki; Kato, Yukihiko; Momose, Yoko; Arai, Satoru; Eto, Hikaru; Ikeda, Takaharu; Furukawa, Fukumi.

In: Modern Rheumatology, Vol. 23, No. 2, 03.2013, p. 318-322.

Research output: Contribution to journalArticle

Yokogawa, Naoto ; Tanikawa, Akiko ; Amagai, Masayuki ; Kato, Yukihiko ; Momose, Yoko ; Arai, Satoru ; Eto, Hikaru ; Ikeda, Takaharu ; Furukawa, Fukumi. / Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). In: Modern Rheumatology. 2013 ; Vol. 23, No. 2. pp. 318-322.
@article{c5620caad1ab44759e5aa829ddc33edf,
title = "Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)",
abstract = "Background: Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupusrelated skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Methods: Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity. Results: Twenty-seven patients, including 17 with SLE (6 with SLE/Sj{\"o}gren's syndrome), were analyzed retrospectively. Twenty-three patients (85 {\%}) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p<0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 {\%}, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p<0.0001). Conclusions: CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.",
keywords = "Cutaneous lupus erythematosus, Cutaneous lupus erythematosus disease area and severity index (CLASI), Hydroxychloroquine, Systemic lupus erythematosus",
author = "Naoto Yokogawa and Akiko Tanikawa and Masayuki Amagai and Yukihiko Kato and Yoko Momose and Satoru Arai and Hikaru Eto and Takaharu Ikeda and Fukumi Furukawa",
year = "2013",
month = "3",
doi = "10.1007/s10165-012-0656-3",
language = "English",
volume = "23",
pages = "318--322",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)

AU - Yokogawa, Naoto

AU - Tanikawa, Akiko

AU - Amagai, Masayuki

AU - Kato, Yukihiko

AU - Momose, Yoko

AU - Arai, Satoru

AU - Eto, Hikaru

AU - Ikeda, Takaharu

AU - Furukawa, Fukumi

PY - 2013/3

Y1 - 2013/3

N2 - Background: Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupusrelated skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Methods: Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity. Results: Twenty-seven patients, including 17 with SLE (6 with SLE/Sjögren's syndrome), were analyzed retrospectively. Twenty-three patients (85 %) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p<0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 %, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p<0.0001). Conclusions: CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.

AB - Background: Hydroxychloroquine (HCQ) is not available in Japan. To design a clinical trial of HCQ, we evaluated the response to HCQ in Japanese patients with lupusrelated skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI). Methods: Twenty-seven patients with lupus-related skin disease who started HCQ at four hospitals were included. Patients were categorized into responders by the CLASI response criteria. The points and the rate of improvement in the CLASI activity score after 16 weeks of treatment were analyzed, focusing on six parameters: systemic lupus erythematosus (SLE), skin manifestations, disease duration, prednisolone, smoking, and severity. Results: Twenty-seven patients, including 17 with SLE (6 with SLE/Sjögren's syndrome), were analyzed retrospectively. Twenty-three patients (85 %) were categorized as responders. The mean CLASI activity score improved from 10.1 to 4.5 (p<0.0001). The improvement rate did not differ in these parameters except for that of annular erythema (81.6 versus 34.3 %, p = 0.036). On multivariate analysis, the baseline CLASI activity score (CLASI ≥9) correlated with the greatest decrease in CLASI activity score (F = 69.7, p<0.0001). Conclusions: CLASI is a reliable indicator to evaluate the efficacy of the drug, and HCQ is an effective treatment for Japanese patients with lupus-related skin disease.

KW - Cutaneous lupus erythematosus

KW - Cutaneous lupus erythematosus disease area and severity index (CLASI)

KW - Hydroxychloroquine

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84883151129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883151129&partnerID=8YFLogxK

U2 - 10.1007/s10165-012-0656-3

DO - 10.1007/s10165-012-0656-3

M3 - Article

C2 - 22581095

AN - SCOPUS:84883151129

VL - 23

SP - 318

EP - 322

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 2

ER -